Skip to main content
Journal cover image

Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.

Publication ,  Journal Article
Melamud, A; Stinnett, S; Fekrat, S
Published in: Am J Ophthalmol
July 2008

PURPOSE: To report the efficacy of treatment of neovascular age-related macular degeneration (AMD) with intravitreal bevacizumab (Avastin; Genentech, Inc, South San Francisco, California, USA) when administered in a series of three monthly injections followed by a period of observation. DESIGN: Retrospective case series. METHODS: Retrospective review of consecutive eyes with all choroidal neovascular lesion subtypes resulting from neovascular AMD treated with intravitreal bevacizumab. Treatment consisted of a pars plana injection of 1.25 mg Avastin (0.05 ml bevacizumab at a concentration of 25 mg/ml). Evaluation consisted of a complete ophthalmologic examination, including best-corrected visual acuity (VA) measurement, ophthalmoscopy, and optical coherence tomography. Eyes received a series of three monthly injections followed by a three-month period of observation. RESULTS: A total of 36 patients (37 eyes) received a series of three consecutive monthly intravitreal injections of bevacizumab. Twenty (54%) of 37 eyes had no previous treatments for neovascular AMD in the eye that received bevacizumab. Seventeen (46%) of 37 eyes had received some previous treatment before initiation of bevacizumab therapy. Intravitreal Avastin therapy produced an improvement in foveal thickness over time in eyes with neovascular AMD. This improvement was sustained during the series of three monthly injections. All eyes experienced worsening after three months without treatment. No statistically significant effect on VA was demonstrated in this series. CONCLUSION: Intravitreal bevacizumab therapy produced an improvement in foveal thickness over time in eyes with neovascular AMD when one injection was given each month for three consecutive months. All eyes experienced increased foveal thickening during the subsequent three months without treatment.

Duke Scholars

Published In

Am J Ophthalmol

DOI

ISSN

0002-9394

Publication Date

July 2008

Volume

146

Issue

1

Start / End Page

91 / 95

Location

United States

Related Subject Headings

  • Vitreous Body
  • Visual Acuity
  • Vascular Endothelial Growth Factor A
  • Treatment Outcome
  • Tomography, Optical Coherence
  • Retrospective Studies
  • Retreatment
  • Ophthalmoscopy
  • Ophthalmology & Optometry
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Melamud, A., Stinnett, S., & Fekrat, S. (2008). Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Am J Ophthalmol, 146(1), 91–95. https://doi.org/10.1016/j.ajo.2008.03.014
Melamud, Alex, Sandra Stinnett, and Sharon Fekrat. “Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.Am J Ophthalmol 146, no. 1 (July 2008): 91–95. https://doi.org/10.1016/j.ajo.2008.03.014.
Melamud, Alex, et al. “Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.Am J Ophthalmol, vol. 146, no. 1, July 2008, pp. 91–95. Pubmed, doi:10.1016/j.ajo.2008.03.014.
Journal cover image

Published In

Am J Ophthalmol

DOI

ISSN

0002-9394

Publication Date

July 2008

Volume

146

Issue

1

Start / End Page

91 / 95

Location

United States

Related Subject Headings

  • Vitreous Body
  • Visual Acuity
  • Vascular Endothelial Growth Factor A
  • Treatment Outcome
  • Tomography, Optical Coherence
  • Retrospective Studies
  • Retreatment
  • Ophthalmoscopy
  • Ophthalmology & Optometry
  • Middle Aged